On March 16, 2023 Novocure (NASDAQ: NVCR) reported the 5th Annual AACR (Free AACR Whitepaper)-Novocure Grants for Tumor Treating Fields Research Program (Press release, NovoCure, MAR 16, 2023, View Source [SID1234628967]). The program represents a joint effort with the American Association for Cancer Research (AACR) (Free AACR Whitepaper) to promote and support innovative research on Tumor Treating Fields (TTFields) as well as to encourage investigators to enter the TTFields research field.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program includes research grants and career development awards totaling more than $1.5 million over the next three years. The grants are intended to provide a deeper understanding of the mechanisms of action of TTFields therapy and to accelerate the development of new treatment strategies to advance therapeutic options for cancer.

The research grants will include three AACR (Free AACR Whitepaper)-Novocure Cancer Research Grants for independent investigators, each totaling $350,000 over three years, and one AACR (Free AACR Whitepaper)-Novocure Career Development Award for Cancer Research for junior faculty members, totaling $300,000 over three years.

"We are proud to continue the AACR (Free AACR Whitepaper)-Novocure partnership," said Mitch Stoller, the AACR (Free AACR Whitepaper)’s Chief Philanthropic Officer. "These grant mechanisms support talented investigators and catalyze advances in TTFields research in a unique way. We look forward to welcoming another class of grantees into the program this fall."

Novocure and the AACR (Free AACR Whitepaper) encourage applicants to focus their proposals on studies promoting the transition of in vitro work into in vivo systems, combination therapies involving TTFields, or translational projects bringing treatments involving TTFields into the clinic. The deadline to submit a letter of intent is May 30, 2023.

"We value the opportunity to collaborate with the AACR (Free AACR Whitepaper), the world’s first and largest cancer research organization, to support research on TTFields," said Moshe Giladi, Novocure’s Chief Science Officer. "As we aspire to make a difference in cancer, we believe TTFields therapy is a platform with game-changing potential. By deepening our understanding of the mechanisms of action behind TTFields, we hope to accelerate discovery that will allow us to help more patients around the world."

To apply for the AACR (Free AACR Whitepaper)-Novocure Grants for Tumor Treating Fields Research, visit www.aacr.org/funding.

About Tumor Treating Fields Therapy

Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.